Court Overseeing Federal Actos Bladder Cancer Litigation Holds June Status Conference, Bernstein Liebhard LLP Reports

(PRWEB) July 06, 2014

The federal court overseeing thousands of Actos lawsuits ( that allege long-term use of the Type-2 diabetes drug caused patients to develop bladder cancer held a Status Conference on June 19, 2014, Bernstein Liebhard LLP reports. According court documents filed in the U.S. District Court, Western District of Louisiana, a number of issues were addressed at that time, including the status of outstanding motions and orders, bellwether trials, and the proceeding’s discovery plan. The litigations next Status Conference has been scheduled for August 21, 2014, at 10:30 a.m. (In re: Actos Product Liability Litigation, MDL No. 2299)

Our Firm continues to hear from Actos patients who allegedly developed bladder cancer due to their use of the medication. We are pleased to see this proceeding moving forward, says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who were treated with Actos for a year or more, and who allegedly went on to develop bladder cancer due to their use of the drug.

Actos Lawsuits

According to court records, more than 3,000 Actos bladder cancer claims are currently pending in the litigation underway in the Western District of Louisiana. Among other things, the Actos lawsuits allege that Takeda Pharmaceuticals, Co., Ltd. and Eli Lily & Co. were aware of the dangers associated with Actos, but refused to warn patients, physicians, and the medical community about its link to bladder cancer. The federal litigation completed its first trial of an Actos lawsuit in April. The case ended with a jury awarding the plaintiff $ 1.475 million in compensatory damages, along with $ 9 billion in punitive damages. (Case No. 12-cv-00064)

According to court documents, the Actos bladder cancer litigation has been mounting since June 2011, when new information was added to the drugs label regarding its potential to cause bladder cancer. The U.S. Food & Drug Administration mandated the label change after interim results from a 10 year study suggested that taking Actos for more than 1 year was associated with a doubling of the risk of bladder cancer.

Long-term users of Actos may be entitled to compensation if they developed bladder cancer, allegedly due to the use of the medication. To find out more about Actos lawsuits, please visit Bernstein Liebhard LLPs website. For additional information, please call 800-511-5092 today.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiffs recovery.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016



Leave a Reply